Download RTF

Publications for Lisa Horvath
Publications for Lisa Horvath
2017
2671-2685. <a
href="http://dx.doi.org/10.1074/mcp.M116.0583
13">[More Information]</a>
Selinger, C., Li, B., Pavlakis, N., Links, M., Gill,
A., Lee, A., Clarke, S., Tran, T., Lum, T., Yip,
P., Horvath, L., Yu, B., O'Toole, S., Cooper, W.,
et al (2017). Screening for ROS1 gene
rearrangements in non-small-cell lung cancers
using immunohistochemistry with FISH
confirmation is an effective method to identify
this rare target. Histopathology, 70(3), 402-411.
<a
href="http://dx.doi.org/10.1111/his.13076">[Mor
e Information]</a>
2015
2016
Gupta, R., O'Connell, R., Haynes, A., Stricker,
P., Barrett, W., Turner, J., Delprado, W.,
Horvath, L., Kench, J. (2015). Extraprostatic
Extension (EPE) of Prostatic Carcinoma: Is its
Proximity to Surgical margin or Gleason Score
Important? BJU International, 116(3), 343-350.
<a
href="http://dx.doi.org/10.1111/bju.12911">[Mo
re Information]</a>
Fromm, P., Papadimitrious, M., Hsu, J., Van
Kooten Losio, N., Verma, N., Ho Lo, T.,
Silveira, P., Bryant, C., Turtle, C., Prue, R.,
Horvath, L., Bradstock, K., Joshua, D., Clark, G.,
Hart, D., et al (2016). CMRF-56+ blood
dendritic cells loaded with mRNA induce
effective antigen-specific cytotoxic
T-lymphocyte responses. OncoImmunology,
5(6), 1-12. <a
href="http://dx.doi.org/10.1080/2162402X.2016.
1168555">[More Information]</a>
Bruce, H., Stricker, P., Gupta, R., Savdie, R.,
Haynes, A., Mahon, K., Lin, H., Kench, J.,
Horvath, L. (2016). Loss of AZGP1 as a
Superior Predictor of Relapse in Margin-Positive
Localized Prostate Cancer. The Prostate, 76(16),
1491-1500. <a
href="http://dx.doi.org/10.1002/pros.23233">[M
ore Information]</a>
Kalsbeek, A., Chan, E., Grogan, J., Petersen, D.,
Jaratlerdsiri, W., Gupta, R., Lyons, R., Haynes,
A., Horvath, L., Kench, J., Hayes, V., et al
(2016). Mutational load of the mitochondrial
genome predicts pathological features and
biochemical recurrence in prostate cancer. Aging,
8(11), 2702-2712. <a
href="http://dx.doi.org/10.18632/aging.101044">
[More Information]</a>
Lomax, A., Beith, J., Bhadri, V., Boyer, M.,
Grimison, P., Horvath, L., Kao, S., Tattersall,
M., Thomas, D., McNeil, C. (2016). Outcomes
of patients with non-melanoma solid tumours
receiving self-funded pembrolizumab at Chris
O'Brien Lifehouse. Internal Medicine Journal,
46(12), 1392-1398. <a
href="http://dx.doi.org/10.1111/imj.13232">[Mo
re Information]</a>
Humphrey, E., Su, S., Nagrial, A., Hochgrafe, F.,
Pajic, M., Lehrbach, G., Parton, R., Yap, A.,
Horvath, L., Chang, D., et al (2016). Resolution
of Novel Pancreatic Ductal Adenocarcinoma
Subtypes by Global Phosphotyrosine Profiling.
Molecular and Cellular Proteomics, 15(8),
Mahon, K., Lin, H., Castillo, L., Lee, B.,
Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S.,
Brown, D., Molloy, M., Marx, G., Pavlakis, N.,
Boyer, M., Stockler, M., Horvath, L., et al
(2015). Cytokine profiling of docetaxel-resistant
castration-resistant prostate cancer. British
Journal of Cancer, 112(8), 1340-1348. <a
href="http://dx.doi.org/10.1038/bjc.2015.74">[M
ore Information]</a>
Lee, B., Timpson, P., Horvath, L., Daly, R.
(2015). FAK Signaling in Human Cancer as a
Target for Therapeutics. Pharmacology &
Therapeutics, 146, 132-149. <a
href="http://dx.doi.org/10.1016/j.pharmthera.201
4.10.001">[More Information]</a>
Yates, A., Carroll, S., Kneebone, A., Tse, R.,
Horvath, L., Byrne, C., Solomon, M., Hruby, G.
(2015). Implementing Intensity-modulated
Radiotherapy with Simultaneous Integrated
Boost for Anal Cancer: 3 Year Outcomes at Two
Sydney Institutions. Clinical Oncology, 27(12),
700-707. <a
href="http://dx.doi.org/10.1016/j.clon.2015.08.0
06">[More Information]</a>
Rynkiewicz, N., Fedele, C., Chiam, K., Gupta,
R., Kench, J., Ooms, L., McLean, C., Giles, G.,
Horvath, L., Mitchell, C. (2015). INPP4B is
highly expressed in prostate intermediate cells
and its loss of expression in prostate carcinoma
predicts for recurrence and poor long term
survival. The Prostate, 75(1), 92-102. <a
href="http://dx.doi.org/10.1002/pros.22895">[M
ore Information]</a>
Cooper, W., Tran, T., Vilain, R., Madore, J.,
Selinger, C., Kohonen-Corish, M., Yip, P., Yu,
B., O'Toole, S., McCaughan, B., Horvath, L.,
Kao, S., Boyer, M., Scolyer, R., et al (2015).
PD-L1 expression is a favorable prognostic
factor in early stage non-small cell carcinoma.
Lung Cancer, 89(2), 181-188. <a
href="http://dx.doi.org/10.1016/j.lungcan.2015.0
5.007">[More Information]</a>
Nagrial, A., Chin, V., Sjoquist, K., Pajic, M.,
Horvath, L., Biankin, A., Yip, D. (2015).
Publications for Lisa Horvath
Second-line treatment in inoperable pancreatic
adenocarcinoma: A systematic review and
synthesis of all clinical trials. Critical Reviews in
Oncology / Hematology (online), 96(3), 483-497.
<a
href="http://dx.doi.org/10.1016/j.critrevonc.2015
.07.007">[More Information]</a>
2014
Nagrial, A., Chang, D., Nguyen, N., Johns, A.,
Chantrill, L., Humphris, J., Chin, V., Samra, J.,
Gill, A., Pajic, M., Kench, J., et al (2014).
Adjuvant chemotherapy in elderly patients with
pancreatic cancer. British Journal of Cancer,
110(2), 313-319. <a
href="http://dx.doi.org/10.1038/bjc.2013.722">[
More Information]</a>
Suttie, C., Hruby, G., Horvath, L., Thompson, J.
(2014). Cardiac metastasis in Merkel cell
carcinoma. Journal of Clinical Oncology, 32(13),
e52-e53. <a
href="http://dx.doi.org/10.1200/JCO.2012.48.30
73">[More Information]</a>
Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee,
B., Nguyen, Q., Boyer, M., Stockler, M.,
Pavlakis, N., Marx, G., Gurney, H., Horvath, L.,
et al (2014). Circulating microRNAs are
associated with docetaxel chemotherapy outcome
in castration-resistant prostate cancer. British
Journal of Cancer, 110(10), 2462-2471. <a
href="http://dx.doi.org/10.1038/bjc.2014.181">[
More Information]</a>
Galletti, G., Matov, A., Beltran, H., Fontugne, J.,
Mosquera, J., Cheung, C., MacDonald, T., Sung,
M., O'Toole, S., Kench, J., Horvath, L., et al
(2014). ERG induces taxane resistance in
castration-resistant prostate cancer. Nature
Communications, 5, 1-12. <a
href="http://dx.doi.org/10.1038/ncomms6548">[
More Information]</a>
Birch, S., Kench, J., Takano, E., Chan, P., Chan,
A., Chiam, K., Veillard, A., Stricker, P., Haupt,
S., Haupt, Y., Horvath, L., et al (2014).
Expression of E6AP and PML predicts for
prostate cancer progression and cancer-specific
death. Annals of Oncology, 25(12), 2392-2397.
<a
href="http://dx.doi.org/10.1093/annonc/mdu454"
>[More Information]</a>
Sutherland, S., Pe Benito, R., Henshall, S.,
Horvath, L., Kench, J. (2014). Expression of
phosphorylated-mTOR during the development
of prostate cancer. The Prostate, 74(12),
1231-1239. <a
href="http://dx.doi.org/10.1002/pros.22840">[M
ore Information]</a>
Mahon, K., Qu, W., Devaney, J., Paul, C.,
Castillo, L., Wykes, R., Chatfield, M., Boyer,
M., Stockler, M., Marx, G., Gurney, H., Horvath,
L., et al (2014). Methylated Glutathione
S-transferase 1 (mGSTP1) is a potential plasma
free DNA epigenetic marker of prognosis and
response to chemotherapy in castrate-resistant
prostate cancer. British Journal of Cancer,
111(9), 1802-1809. <a
href="http://dx.doi.org/10.1038/bjc.2014.463">[
More Information]</a>
Lee, B., Hochgrafe, F., Lin, H., Castillo, L., Wu,
J., Raftery, M., Shreeve, S., Horvath, L., Daly, R.
(2014). Phosphoproteomic profiling identifies
focal adhesion kinase as a mediator of docetaxel
resistance in castrate-resistant prostate cancer.
Molecular Cancer Therapeutics, 13(1), 190-201.
<a
href="http://dx.doi.org/10.1158/1535-7163.MCT
-13-0225-T">[More Information]</a>
Yip, P., Cooper, W., Kohonen-Corish, M., Lin,
B., McCaughan, B., Boyer, M., Kench, J.,
Horvath, L. (2014). Phosphorylated Akt
expression is a prognostic marker in early-stage
non-small cell lung cancer. Journal of Clinical
Pathology, 67(4), 333-340. <a
href="http://dx.doi.org/10.1136/jclinpath-2013-2
01870">[More Information]</a>
2013
Selth, L., Townley, S., Bert, A., Stricker, P.,
Sutherland, P., Horvath, L., Goodall, G., Butler,
L., Tilley, W. (2013). Circulating microRNAs
predict biochemical recurrence in prostate cancer
patients. British Journal of Cancer, 109(3),
641-650. <a
href="http://dx.doi.org/10.1038/bjc.2013.369">[
More Information]</a>
Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T.,
Farzin, M., Trent, R., Mercorella, B., Clarkson,
A., Kohonen-Corish, M., Horvath, L., Kench, J.,
McCaughan, B., Gill, A., O'Toole, S. (2013).
EGFR mutant-specific immunohistochemistry
has high specificity and sensitivity for detecting
targeted activating EGFR mutations in lung
adenocarcinoma. Journal of Clinical Pathology,
66(9), 744-748. <a
href="http://dx.doi.org/10.1136/jclinpath-2013-2
01607">[More Information]</a>
Hulf, T., Sibbritt, T., Wiklund, E., Patterson, K.,
Song, J., Stirzaker, C., Qu, W., Nair, S., Horvath,
L., Armstrong, N., et al (2013).
Epigenetic-induced repression of microRNA-205
is associated with MED1 activation and a poorer
prognosis in localized prostate cancer.
Oncogene, 32(23), 2891-2899. <a
href="http://dx.doi.org/10.1038/onc.2012.300">[
More Information]</a>
Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C.,
Kennedy, C., Kohonen-Corish, M., McCaughan,
B., Trent, R., Boyer, M., Kench, J., Horvath, L.,
Publications for Lisa Horvath
O'Toole, S. (2013). Patterns of DNA mutations
and ALK Rearrangement in Resected Node
Negative Lung Adenocarcinoma. Journal of
Thoracic Oncology, 8(4), 408-414. <a
href="http://dx.doi.org/10.1097/JTO.0b013e3182
83558e">[More Information]</a>
integrated with concomitant 5FU and 3-D
conformal radiotherapy for the treatment of
localised pancreatic cancer. British Journal of
Cancer, 106(1), 61-69. <a
href="http://dx.doi.org/10.1038/bjc.2011.526">[
More Information]</a>
Selinger, C., Rogers, T., Russell, P., O'Toole, S.,
Yip, P., Wright, G., Wainer, Z., Horvath, L.,
Boyer, M., McCaughan, B., et al (2013). Testing
for ALK rearrangement in lung adenocarcinoma:
A multicenter comparison of
immunohistochemistry and fluorescent in situ
hybridization. Modern Pathology, 26(12),
1545-1553. <a
href="http://dx.doi.org/10.1038/modpathol.2013.
87">[More Information]</a>
2011
2012
Venkateswaran, L., Butow, P., Jansen, J.,
Wilcken, N., WONG, M., Hui, R., Szonyi, G.,
Gebski, V., Naganathan, V., Horvath, L.,
Tattersall, M. (2012). Decision making in older
patients with advanced cancer: Does doctor
know best? Medical Journal of Australia, 196(1),
35-39. <a
href="http://dx.doi.org/10.5694/mja11.10907">[
More Information]</a>
Savdie, R., Horvath, L., Pe Benito, R., Rasiah,
K., Haynes, A., Chatfield, M., Stricker, P.,
Turner, J., Delprado, W., Henshall, S., Kench, J.,
et al (2012). High Gleason grade carcinoma at a
positive surgical margin predicts biochemical
failure after radical prostatectomy and may guide
adjuvant radiotherapy. BJU International,
109(12), 1794-1800. <a
href="http://dx.doi.org/10.1111/j.1464-410X.201
1.10572.x">[More Information]</a>
Femia, J., Hardy, T., Spies, J., Horvath, L.
(2012). Posterior reversible encephalopathy
syndrome following chemotherapy with
oxaliplatin and a fluoropyrimidine: A case report
and literature review. Asia-Pacific Journal of
Clinical Oncology, 8(2), 115-122. <a
href="http://dx.doi.org/10.1111/j.1743-7563.201
2.01544.x">[More Information]</a>
Randall, S., McKay, M., Pascovici, D., Mahon,
K., Horvath, L., Clarke, S., Molloy, M. (2012).
Remarkable temporal stability of high-abundance
human plasma proteins assessed by targeted
mass spectrometry. Proteomics - Clinical
Applications, 6(11-12), 626-634. <a
href="http://dx.doi.org/10.1002/prca.201200039"
>[More Information]</a>
Goldstein, D., Spry, N., Cummins, M., Brown,
C., van Hazel, G., Carroll, S., Selva-Nayagam,
S., Borg, M., Ackland, S., Wratten, C., Hruby,
G., Horvath, L., Gebski, V., et al (2012). The
GOFURTGO Study: AGITG Phase II Study of
fixed dose rate gemcitabine-oxaliplatin
Devaney, J., Stirzaker, C., Qu, W., Song, J.,
Statham, A., Patterson, K., Horvath, L., Tabor,
B., Coolen, M., Hulf, T., Kench, J., et al (2011).
Epigenetic Deregulation Across Chromosome
2q14.2 Differentiates Normal from Prostate
Cancer and Provides a Regional Panel of Novel
DNA Methylation Cancer Biomarkers. Cancer
Epidemiology, Biomarkers and Prevention,
20(1), 148-159. <a
href="http://dx.doi.org/10.1158/1055-9965.EPI-1
0-0719">[More Information]</a>
Mahon, K., Henshall, S., Sutherland, R.,
Horvath, L. (2011). Pathways of chemotherapy
resistance in castration-resistant prostate cancer.
Endocrine-Related Cancer, 18(4), R103-R123.
<a
href="http://dx.doi.org/10.1530/ERC-10-0343">[
More Information]</a>
Kench, J., Clouston, D., Delprado, W., Eade, T.,
Ellis, D., Horvath, L., Samaratunga, H., Stahl, J.,
Stapleton, A., Egevad, L., et al (2011).
Prognostic factors in prostate cancer. Key
elements in structured histopathology reporting
of radical prostatectomy specimens. Pathology,
43(5), 410-419. <a
href="http://dx.doi.org/10.1097/PAT.0b013e328
348a6b3">[More Information]</a>
Leighl, N., Shepherd, H., Butow, P., Clarke, S.,
McJannett, M., Beale, P., Wilcken, N., Moore,
M., Chen, E., Goldstein, D., Horvath, L.,
Tattersall, M., et al (2011). Supporting Treatment
Decision Making in Advanced Cancer: A
Randomized Trial of a Decision Aid for Patients
With Advanced Colorectal Cancer Considering
Chemotherapy. Journal of Clinical Oncology,
29(15), 2077-2084. <a
href="http://dx.doi.org/10.1200/JCO.2010.32.07
54">[More Information]</a>
Cooper, W., O'Toole, S., Boyer, M., Horvath, L.,
Mahar, A. (2011). What's new in non-small cell
lung cancer for pathologists: the importance of
accurate subtyping, EGFR mutations and ALK
rearrangements. Pathology, 43(2), 103-115. <a
href="http://dx.doi.org/10.1097/PAT.0b013e328
342629d">[More Information]</a>
2010
Nagrial, A., Horvath, L. (2010). Bone disease in
prostate cancer. Asia-Pacific Journal of Clinical
Oncology, 6(1), 3-4. <a
href="http://dx.doi.org/10.1111/j.1743-7563.201
Publications for Lisa Horvath
0.01281.x">[More Information]</a>
Ocean, A., Polite, B., Christos, P., Horvath, L.,
Hamilton, A., Matulich, D., Chen, H., Sparano,
J., Kindler, H. (2010). Cetuximab is Associated
with Excessive Toxicity when Combined with
Bevacizumab Plus mFOLFOX6 in Metastatic
Colorectal Carcinoma. Clinical Colorectal
Cancer, 9(5), 290-296. <a
href="http://dx.doi.org/10.3816/CCC.2010.n.042
">[More Information]</a>
Bianco-Miotto, T., Chiam, K., Buchanan, G.,
Jindal, S., Day, T., Thomas, M., Pickering, M.,
O'Loughlin, M., Ryan, N., Raymond, W.,
Horvath, L., Kench, J., et al (2010). Global
Levels of Specific Histone Modifications and an
Epigenetic Gene Signature Predict Prostate
Cancer Progression and Development. Cancer
Epidemiology, Biomarkers and Prevention,
19(10), 2611-2622. <a
href="http://dx.doi.org/10.1158/1055-9965.EPI-1
0-0555">[More Information]</a>
href="http://dx.doi.org/10.1158/1055-9965.EPI-0
8-0204">[More Information]</a>
2006
Sharma, R., Rivory, L., Beale, P., Ong, S.,
Horvath, L., Clarke, S. (2006). A phase II study
of fixed-dose capecitabine and assessment of
predictors of toxicity in patients with
advanced/metastatic colorectal cancer. British
Journal of Cancer, 94(7), 964-968. <a
href="http://dx.doi.org/10.1038/sj.bjc.6603049">
[More Information]</a>
2009
Rasiah, K., Kench, J., Gardiner-Garden, M.,
Biankin, A., Golovsky, D., Brenner, P., Kooner,
R., O'Neill, G., Turner, J., Delprado, W., Lee, C.,
Horvath, L., et al (2006). Aberrant neuropeptide
Y and macrophage inhibitory cytokine-1
expression are early events in prostate cancer
development and are associated with poor
prognosis. Cancer Epidemiology, Biomarkers
and Prevention, 15(4), 711-716. <a
href="http://dx.doi.org/10.1158/1055-9965.EPI-0
5-0752">[More Information]</a>
Balanathan, P., Williams, E., Wang, H.,
Pedersen, J., Horvath, L., Achen, M., Stacker, S.,
Risbridger, G. (2009). Elevated level of
inhibin-alpha subunit is pro-tumourigenic and
pro-metastatic and associated with extracapsular
spread in advanced prostate cancer. British
Journal of Cancer, 100(11), 1784-1793. <a
href="http://dx.doi.org/10.1038/sj.bjc.6605089">
[More Information]</a>
Henshall, S., Horvath, L., Quinn, D., Eggleton,
S., Grygiel, J., Stricker, P., Biankin, A., Kench,
J., Sutherland, R. (2006).
Zinc-alpha2-glycoprotein expression as a
predictor of metastatic prostate cancer following
radical prostatectomy. Journal of the National
Cancer Institute, 98(19), 1420-1424. <a
href="http://dx.doi.org/10.1093/jnci/djj378">[M
ore Information]</a>
Thanigasalam, R., Rasiah, K., Stricker, P.,
Haynes, A., Sutherland, S., Sutherland, R.,
Henshall, S., Horvath, L. (2009). Stage migration
in localized prostate cancer has no effect on the
post-radical prostatectomy Kattan nomogram.
BJU International, 105(5), 642-647. <a
href="http://dx.doi.org/10.1111/j.1464-410X.200
9.08842.x">[More Information]</a>
2005
2008
Read, J., Beale, P., Horvath, L., Volker, D.,
Childs, A., Smith, N., Clarke, S. (2005). Impact
of fish-oil supplement on nutritional parameters,
inflammation and chemotherapy induced toxicity
in colorectal cancer (CRC) patients receiving
FOLFIRI - A pilot study. Journal of Clinical
Oncology, 23(16S (supplement)), Abstract 8243
S789-S789.
Seng, T., Currey, N., Cooper, W., Lee, C., Chan,
C., Sutherland, R., Horvath, L., Kennedy, C.,
McCaughan, B., Kohonen-Corish, M. (2008).
DLEC1 and MLH1 promoter methylation are
associated with poor prognosis in non-small cell
lung carcinoma. British Journal of Cancer,
99(2), 375-382. <a
href="http://dx.doi.org/10.1038/sj.bjc.6604452">
[More Information]</a>
Horvath, L., Henshall, S., Lee, C., Kench, J.,
Golovsky, D., Brenner, P., O'Neill, G., Kooner,
R., Stricker, P., Grygiel, J., et al (2005). Lower
levels of nuclear beta-catenin predict for a poorer
prognosis in localized prostate cancer.
International Journal of Cancer, 113(3),
415-422. <a
href="http://dx.doi.org/10.1002/ijc.20599">[Mor
e Information]</a>
Sakko, A., Butler, M., Byers, S., Reinboth, B.,
Stahl, J., Kench, J., Horvath, L., Sutherland, R.,
Stricker, P., Henshall, S., et al (2008).
Immunohistochemical level of unsulfated
chondroitin disaccharides in the cancer stroma is
an independent predictor of prostate cancer
relapse. Cancer Epidemiology, Biomarkers and
Prevention, 17(9), 2488-2497. <a